Proton pump inhibitors in the practice of physician


DOI: https://dx.doi.org/10.18565/therapy.2019.5.120-126

Kucheryavy Yu.A., Andreev D.N., Shaburov R.I.

A.I. Evdokimov Moscow State University of medicine and dentistry of the Ministry of Healthcare of Russia
Article presents the results of key studies in the sphere of pharmacotherapy with proton pump inhibitors (PPIs) of the most common acid-dependent diseases (ADD) of the upper gastrointestinal tract segment, demonstrating the fact of high demand for medicaments of this class and the variability of the efficacy of medicaments of different generations. Esomeprazole is the first in history stereoisomer of PPI and the most studied drug in this group. He successfully solves the problems of treatment of any ADD, having significant advantages in clinical efficacy comparatively to all PPIs of previous generations.
Keywords: NSAID gastropathy, acid-dependent diseases, esomeprazole, peptic ulcer, proton pump inhibitors, gastroesophageal reflux disease, treatment
Read entire article

Literature


  1. Руководство по внутренней медицине. Под ред. Г.П. Арутюнова, А.И. Мартынова, А.А. Спасского. М., 2015.

  2. Маев И.В., Самсонов А.А., Андреев Н.Г., Андреев Д.Н. Важные практические результаты и современные тенденции в изучении заболеваний желудка и двенадцатиперстной кишки. Росс. журн. гастроэнтерол., гепатол., колопроктол. 2012; 4: 17–26.

  3. Lassen A.T. Acid-related disorders and use of antisecretory medication. Dan Med Bull. 2007; 54(1): 18–30.

  4. Кучерявый Ю.А., Андреев Д.Н. Перспективы лечения больных с кислотозависимыми заболеваниями. Клин. перспективы гастроэнтерол., гепатол. 2014; 2: 15–24.

  5. Маев И.В., Андреев Д.Н., Заборовский А.В. Фундаментальные основы кислотопродукции в желудке. Медицинский совет. 2018; 3: 7–14.

  6. Schubert M.L. Physiologic, pathophysiologic, and pharmacologic regulation of gastric acid secretion. Curr Opin Gastroenterol. 2017; 33(6): 430–38.

  7. Федеральное руководство по использованию лекарственных средств (формулярная система). Выпуск ХVIII. М.: Видокс, 2017.

  8. Mejia A., Kraft W.K. Acid peptic diseases: pharmacological approach to treatment. Expert Rev Clin Pharmacol. 2009; 2(3): 295–314.

  9. Андреев Д.Н., Кучерявый Ю.А. Перспективы лечения гастроэзофагеальной рефлюксной болезни. Гастроэнтерология. Приложение к журналу Consilium Medicum. 2013; 2: 9–14.

  10. Sleisenger and Fordtran’s Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management. Ed. by Mark Feldman, Lawrence S Friedman, Laurence J Brandt. 10th ed. 2015.

  11. Desta Z.X., Shin J.G., Flockhart D.A. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin. Pharmacokinet. 2002; 41(12): 913–58. doi: 10.2165/00003088-200241120-00002.

  12. Li-Wan-Po A., Girard T., Farndon P., Cooley C., Lithgow J. Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17. Br J Clin Pharmacol. 2010; 69(3): 222–30. doi: 10.1111/j.1365-2125.2009.03578.x.

  13. Serrano D., Torrado S., Torrado-Santiago S., Gisbert J.P. The influence of CYP2C19 genetic polymorphism on the pharmacokinetics/- pharmacodynamics of proton pump inhibitor-containing Helicobacter pylori treatments. Curr Drug Metab. 2012; 13(9): 1303–12.

  14. Chaudhry A.S., Kochhar R., Kohli K.K. Genetic polymorphism of CYP2C19 & therapeutic response to proton pump inhibitors. Indian J. Med. Res. 2008; 127(6): 521–30.

  15. Маев И.В., Андреев Д.Н. Молекулярно-генетические предикторы резистентности к антихеликобактерной терапии. Терапевтический архив. 2017; 89(8): 5–12

  16. Johnson T.J., Hedge D.D. Esomeprazole: a clinical review. Am. J. Health Syst. Pharm. 2002; 59(14): 1333–39.

  17. Scott L.J., Dunn C.J., Mallarkey G. et al. Esomeprazole: a review of its use in the management of acid-related disorders. Drugs. 2002; 62(10): 1503–38.

  18. Abelo A., Andersson T.B., Bredberg U. et al. Stereoselective metabolism by human liver CYP enzymes of a substituted benzimidazole. Drug Metab. Dispos. 2000; 28(1): 58–64.

  19. Andersson T., Hassan-Alin M., Hasselgren G. et al. Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole. Clin. Pharmacokinet. 2001; 40(6): 411–26.

  20. Miner P. Jr., Katz P.O., Chen Y. et al. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am. J. Gastroenterol. 2003; 98(12): 2616–20.

  21. Маев И.В., Бусарова Г.А., Андреев Д.Н. Болезни пищевода. М.: ГЭОТАР-Медиа, 2019.

  22. Ивашкин В.Т., Маев И.В., Трухманов А.С. с соавт. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению гастроэзофагеальной рефлюксной болезни. Российский журнал гастроэнтерологии, гепатологии и колопроктологии. 2017; 27(4): 75–95.

  23. Savarino E., Marabotto E., Bodini G. et al. Epidemiology and natural history of gastroesophageal reflux disease. Minerva Gastroenterol Dietol. 2017 Sep; 63(3): 175–183. doi: 10.23736/S1121-421X.17.02383-2.

  24. Eusebi L.H., Ratnakumaran R., Yuan Y. et al. Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: a meta-analysis. Gut. 2018 Mar; 67(3): 430–40. doi: 10.1136/gutjnl-2016-313589.

  25. Katz P.O., Gerson L.B., Vela M.F. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013 Mar; 108(3): 308–28; quiz 329. doi: 10.1038/ajg.2012.444.

  26. Iwakiri K., Kinoshita Y., Habu Y. et al. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015. J Gastroenterol. 2016 Aug; 51(8): 751–67. doi: 10.1007/s00535-016-1227-8. Epub 2016 Jun 21.

  27. Hunt R., Armstrong D., Katelaris P. et al. World Gastroenterology Organisation Global Guidelines: GERD Global Perspective on Gastroesophageal Reflux Disease. J Clin Gastroenterol. 2017 Jul; 51(6): 467–78. doi: 10.1097/MCG.0000000000000854.

  28. Kastelein F., Spaander M.C., Steyerberg E.W. et al. Proton pump inhibitors reduce the risk of neoplastic progression in patients with Barrett’s esophagus. Clin Gastroenterol Hepatol. 2013 Apr; 11(4): 382–88. doi: 10.1016/j.cgh.2012.11.014.

  29. Weijenborg P.W., Cremonini F., Smout A.J., Bredenoord A.J. PPI therapy is equally effective in well-defined non-erosive reflux disease and in reflux esophagitis: a meta-analysis. Neurogastroenterol Motil. 2012 Aug; 24(8): 747–57, e350. doi: 10.1111/j.1365-2982.2012.01888.x. Epub 2012 Feb 6.

  30. Li M.J., Li Q., Sun M., Liu L.Q. Comparative effectiveness and acceptability of the FDA-licensed proton pump inhibitors for erosive esophagitis: A PRISMA-compliant network meta-analysis. Medicine (Baltimore). 2017 Sep; 96(39): e8120. doi: 10.1097/MD.0000000000008120.

  31. Teng M., Khoo A.L., Zhao Y.J. et al. Meta-analysis of the effectiveness of esomeprazole in gastroesophageal reflux disease and Helicobacter pylori infection. J Clin Pharm Ther. 2015 Aug; 40(4): 368–75. doi: 10.1111/jcpt.12277.

  32. Qi Q., Wang R., Liu L., Zhao F., Wang S. Comparative effectiveness and tolerability of esomeprazole and omeprazole in gastro-esophageal reflux disease: a systematic review and meta-analysis. Int J Clin Pharmacol Ther. 2015 Oct; 53(10): 803–10. doi: 10.5414/CP202396.

  33. Mei J., Yu Y., Ma J., Yu X. Evaluation of the effectiveness of esomeprazole treatment strategies in the management of patients with gastroesophageal reflux disease symptoms: a meta-analysis. Pharmazie. 2016 May; 71(5): 285–91.

  34. Маев И.В., Андреев Д.Н. Инфекция Helicobacter pylori и ассоциированные заболевания. Москва, 2018.

  35. Андреев Д.Н., Оганесян Т.С., Кучерявый Ю.А., Андреев Н.Г. Язвенная болезнь желудка и двенадцатиперстной кишки: диагностика и лечение. Справочник поликлинического врача. 2014; 10: 42–44.

  36. Lanas A., Chan F.K. Peptic ulcer disease. Lancet. 2017; 390(10094): 613–24.

  37. Kusters J.G, van Vliet A.H., Kuipers E.J. Pathogenesis of Helicobacter pylori infection. Clin. Microbiol. Rev. 2006; 19(3): 449–90.

  38. Андреев Д.Н., Дичева Д.Т., Маев И.В. Возможности оптимизации эрадикационной терапии инфекции Helicobacter pylori в современной клинической практике. Терапевтический архив. 2017; 2: 76–83.

  39. Malfertheiner P., Megraud F., O’Morain C.A. et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017; 66(1): 6–30.

  40. Andreev D. Helicobacter pylori eradication therapy: current regimens. Adv Res Gastroentero Hepatol. 2017; 7 (2): 555710.

  41. Маев И.В., Андреев Д.Н., Самсонов А.А., Велиев А.М. Современные схемы эрадикационной терапии инфекции Helicobacter pylori: стратегия дифференцированного применения, эффективность и безопасность. Экспериментальная и клиническая гастроэнтерология. 2017; 140(4): 103–110.

  42. Labenz J. Current role of acid suppressants in Helicobacter pylori eradication therapy. Best Pract Res Clin Gastroenterol 2001; 15: 413–31.

  43. De Francesco V., Ierardi E., Hassan C., Zullo A. Helicobacter pylori therapy: present and future. World J Gastrointest Pharmacol Ther. 2012; 3(4): 68–73.

  44. Erah P.O., Goddard A.F., Barrett D.A., Shaw P.N., Spiller R.C. The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: relevance to the treatment of Helicobacter pylori infection. J Antimicrob Chemother. 1997; 39(1): 5–12.

  45. Андреев Д.Н., Велиев А.М. Значение адекватной кислотосупрессии в рамках терапии Helicobacter pylori-ассоциированных заболеваний. Медицинский совет. 2018; 3: 18–21.

  46. Ford A.C., Delaney B.C., Forman D., Moayyedi P. Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients. Cochrane Database Syst Rev. 2006; 2: CD003840.

  47. Wong C.S., Chia C.F., Lee H.C. et al. Eradication of Helicobacter pylori for prevention of ulcer recurrence after simple closure of perforated peptic ulcer: a meta-analysis of randomized controlled trials. J Surg Res. 2013; 182(2): 219–26.

  48. McNicholl A.G., Linares P.M., Nyssen O.P., Calvet X., Gisbert J.P. Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther. 2012; 36 (5): 414–25.

  49. Маев И.В., Андреев Д.Н., Дичева Д.Т., Кучерявый Ю.А., Заборовский А.В., Парцваниа-Виноградова Е.В. Диагностика и лечение инфекции Helicobacter pylori: положения консенсуса маастрихт v (2015 г.). Архивъ внутренней медицины. 2017; 7(2): 85–94.

  50. Denisenko N.P., Sychev D.A., Sizova Zh.M., Grachev A.V., Velikolug K.A. High frequency of CYP2C19 ultrarapid metabolizers in Russian patients with peptic ulcer. Eksp Klin Gastroenterol. 2015; 6: 11–15.

  51. Маев И.В., Андреев Д.Н., Дичева Д.Т. Гастропатии, индуцированные нестероидными противовоспалительными средствами: патогенетически обоснованные подходы к профилактике и терапии. Фарматека. 2016; 2: 49–54.

  52. Laine L. The role of proton pump inhibitors in NSAID — associated gastropathy and upper gastrointestinal symptoms. Reviews in Gastroenterological Disorders. 2003; 3(4): S30–S39.

  53. Laine L. Proton pump inhibitor co-therapy with nonsteroidal anti-inflammatory drugs — nice or necessary? Reviews in Gastroenterological Disorders. 2004; 4(supplement 4): S33–S41.

  54. Yang M., He M., Zhao M. et al. Proton pump inhibitors for preventing non-steroidal anti-inflammatory drug induced gastrointestinal toxicity: a systematic review. Curr Med Res Opin. 2017 Jun; 33(6): 973–980.


About the Autors

Yuri Al. Kucheryavyy, PhD, associate professor of the Department of propaedeutics of internal medicine and gastroenterology of A.I. Evdokimov Moscow State University of medicine and dentistry of the Ministry of Healthcare of Russia, researcher of the laboratory of functional research methods in gastroenterology of A.I. Evdokimov Moscow state university of medicine and dentistry. Address: 125367, Moscow, 84 Volokolamskoe Highway.
Dmitry N. Andreev, PhD, associate professor of the Department of propaedeutics of internal medicine and gastroenterology of A.I. Evdokimov Moscow state university of medicine and dentistry, researcher of the laboratory of functional research methods in gastroenterology of A.I. Evdokimov Moscow State University of medicine and dentistry. Address: 125367, Moscow, 84 Volokolamskoe Highway. Tel: +7 (905) 524-25-53. E-mail: dna-mit8@mail.ru
Rafik I. Shaburov, PhD, assistant of the Department of propaedeutics of internal medicine and gastroenterology of A.I. Evdokimov Moscow state university of medicine and dentistry, researcher of the laboratory of functional research methods in gastroenterology of A.I. Evdokimov Moscow State University of medicine and dentistry. Address: 125367, Moscow, 84 Volokolamskoe Highway.


Similar Articles

Back to Content

Бионика Медиа